<DOC>
	<DOCNO>NCT00049608</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , gemcitabine , use different way stop tumor cell divide stop grow die . Mistletoe may slow growth tumor cell may effective treatment solid tumor . PURPOSE : Phase I trial study effectiveness combine gemcitabine mistletoe treat patient advance solid tumor .</brief_summary>
	<brief_title>Gemcitabine Combined With Mistletoe Treating Patients With Advanced Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose gemcitabine mistletoe patient advance solid tumor . - Determine toxic effect regimen patient . - Determine pharmacokinetic effect gemcitabine without mistletoe patient . - Determine tumor response patient treat regimen . - Determine time neutrophil count recovery patient treat regimen . OUTLINE : This open-label , dose-escalation study . Patients receive gemcitabine IV 30 minute day 1 8 mistletoe subcutaneously daily start day 8 course 1 . Treatment repeat every 21 day least 3 course absence disease progression unacceptable toxicity . Patients receive escalate dos gemcitabine mistletoe 2 stage . - Stage I : Cohorts 3-6 patient receive escalate dos mistletoe combination constant dose gemcitabine maximum tolerate dose ( MTD ) mistletoe determine . - Stage II : Cohorts 3-6 patient receive escalate dos gemcitabine combination MTD mistletoe determine stage I MTD gemcitabine determine . In stage , MTD define dose precede 2 patient experience dose-limiting toxicity . PROJECTED ACCRUAL : A total 45-51 patient accrue study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm metastatic , recurrent , unresectable locally advanced solid tumor , include one following : Breast colorectal cancer fail firstline chemotherapy Nonsmall cell lung cancer Pancreatic Cancer No CNS metastases Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Age 18 Sex Male female Menopausal status Not specify Performance status ECOG 01 Life expectancy Not specify Hematopoietic Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hepatic Bilirubin great 2.0 mg/dL No clinically significant hepatic dysfunction Renal Creatinine great 2.5 mg/dL No clinically significant renal dysfunction Other Not pregnant nursing Negative pregnancy test HIV negative No clinically significant unrelated illness ( e.g. , serious infection organ dysfunction ) would preclude study tolerance PRIOR CONCURRENT THERAPY : Biologic therapy No prior mistletoe Chemotherapy See Disease Characteristics No prior gemcitabine More 30 day since prior chemotherapy recover Endocrine therapy More 30 day since prior glucocorticosteroid therapy Radiotherapy Recovered prior radiotherapy Surgery Recovered prior surgery Other At least 30 day since prior investigational agent No concurrent investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2007</verification_date>
	<keyword>male breast cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
	<keyword>recurrent colon cancer</keyword>
	<keyword>recurrent non-small cell lung cancer</keyword>
	<keyword>recurrent pancreatic cancer</keyword>
	<keyword>recurrent rectal cancer</keyword>
	<keyword>stage III colon cancer</keyword>
	<keyword>stage III pancreatic cancer</keyword>
	<keyword>stage III rectal cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
	<keyword>stage IIIC breast cancer</keyword>
	<keyword>stage IV breast cancer</keyword>
	<keyword>stage IV colon cancer</keyword>
	<keyword>stage IV non-small cell lung cancer</keyword>
	<keyword>stage IV rectal cancer</keyword>
	<keyword>stage IIIA non-small cell lung cancer</keyword>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
	<keyword>stage IV pancreatic cancer</keyword>
</DOC>